Tin tức & Cập nhật

A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).

The week-96 LATA trial results demonstrate the superiority of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) to tenofovir/lamivudine/dolutegravir (TLD) for maintaining virologic suppression in adolescents with HIV in sub-Saharan Africa.

Three years post-initial US FDA approval, lecanemab still shows ongoing clinical benefits and reduces amyloid plaques in patients with early Alzheimer’s disease (AD).